Affimed (NASDAQ:AFMD) Shares Down 11.1%

Shares of Affimed NV (NASDAQ:AFMD) fell 11.1% during mid-day trading on Friday . The company traded as low as $2.53 and last traded at $2.57, 2,433,867 shares traded hands during mid-day trading. An increase of 235% from the average session volume of 726,686 shares. The stock had previously closed at $2.89.

A number of research firms have recently issued reports on AFMD. Zacks Investment Research lowered Affimed from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. ValuEngine upgraded Affimed from a “sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $6.36.

The business has a 50 day simple moving average of $2.96 and a two-hundred day simple moving average of $3.03. The stock has a market cap of $190.91 million, a price-to-earnings ratio of -6.76 and a beta of 2.91. The company has a current ratio of 3.48, a quick ratio of 3.47 and a debt-to-equity ratio of 0.02.

Affimed (NASDAQ:AFMD) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.16). The firm had revenue of $4.50 million during the quarter, compared to analysts’ expectations of $6.46 million. Affimed had a negative return on equity of 30.94% and a negative net margin of 30.87%. Research analysts anticipate that Affimed NV will post -0.08 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in AFMD. BlackRock Inc. bought a new position in shares of Affimed in the 2nd quarter valued at about $8,399,000. Acadian Asset Management LLC grew its holdings in shares of Affimed by 3,524.2% in the 2nd quarter. Acadian Asset Management LLC now owns 2,176,604 shares of the biopharmaceutical company’s stock valued at $6,247,000 after acquiring an additional 2,116,546 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Affimed in the 3rd quarter valued at about $1,051,000. Stonepine Capital Management LLC grew its holdings in shares of Affimed by 41.5% in the 2nd quarter. Stonepine Capital Management LLC now owns 715,754 shares of the biopharmaceutical company’s stock valued at $2,054,000 after acquiring an additional 210,018 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of Affimed in the 2nd quarter valued at about $574,000. Institutional investors own 51.01% of the company’s stock.

Affimed Company Profile (NASDAQ:AFMD)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit